Investors

Cue Biopharma is a clinical-stage biopharmaceutical company focused on advancing a robust portfolio of therapies aimed at enabling functional cures across allergic and autoimmune diseases.

Our lead asset, CUE-221, is a novel anti-IgE antibody with a dual mechanism of action, currently in Phase 2 development for allergic diseases. In addition, we developed the Immuno-STAT® platform designed to engineer therapies that selectively target disease-specific T cells in vivo without broad immune modulation. CUE-401, our lead asset targeting autoimmune disease was developed using the Immuno-STAT® platform. It is a bifunctional IL-2 and TGF-β molecule advancing towards Phase 1 and was designed to restore immune balance utilizing Treg-mediated tolerance.

Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.